A study in Nature Communications found that older cancer patients have similar outcomes with immune checkpoint inhibitors as ...

4, 7 and 10) and/or 0.2 mg/dose CTLA-4-Ig (days 0, 2, 4 and 6 after transplantation). Control recipients received 0.25 mg/dose hamster IgG (days 0, 2, 4, 7 and 10). The grafts were observed daily.

In a commentary accompanying the study, Thomas Yau, MBBS, of the University of Hong Kong, and colleagues noted that anti-CTLA-4-based dual ... while PD-L1 and VEGF blockade with atezolizumab ...

The effects of eIF4A-i combined with PD1 blockade were assessed in ex-vivo co-cultures ... Results: Key negative immune checkpoints and transcription factors including TOX, NFAc2, CTLA-4, LAG3, and ...

Prior research has also established the potential mediation of CTLA-4 inhibitory signaling through dephosphorylation ... showed that the addition of a PP2A inhibitor, LB-100, to PD-1 blockade ...

"Unraveling the Role of Ctla-4 in Intestinal Immune Homeostasis: Insights from a novel Zebrafish Model of Inflammatory Bowel Disease" generates a 14bp deletion/early stop codon mutation that is viable ...

This study focuses on the role of a T-cell-specific receptor, ctla-4, in a new zebrafish model of IBD-like phenotype. Although implicated in IBD diseases, the function of ctla-4 has been hard to study ...

Agenus Inc. , a clinical-stage immuno-oncology company, today announced updated data from the hepatocellular carcinoma (HCC) cohort of its ongoing Phase 1 study evaluating botensilimab (BOT) in ...

Affinity Biopharmaceutical Co., Ltd., Shanghai, China.

Immune checkpoint inhibitors (ICI) have transformed the therapeutic landscape in oncology, improving survival in the metastatic setting in non–small cell lung cancer (NSCLC), 1,2 melanoma, 3,4 and ...